Andersons pediatric cardiology 2339
Bạn đang xem bản rút gọn của tài liệu. Xem và tải ngay bản đầy đủ của tài liệu tại đây (80.33 KB, 3 trang )
1396
CFCandCostellosyndromes,1412–1414
Channelopathies,351–356,352b
Charcot-Marie-Toothdisease,cardiacinvolvementin,1106
Chargesyndrome,1417,1417t
CHDs,Congenitalheartdefects
Chemoreceptors,arterial,incontrolofcirculation,1358–1359
Chemotherapy,forcardiactumors,977
ChestCT,inpulmonaryhypertension,1388
Chestmasses,99
Chestradiography
ofanomaliesoftheaorticarch,888–889,888f–889f
ofpulmonaryarterialsling,892
forpulmonaryhypertension,1387
inpulmonarystenosis,782,782f
Chiarinetwork,519,520f
indiagnosticcatheterization,245
ChildhoodCancerSurvivorStudy(CCSS),incancertherapy-related
cardiotoxicity,1167
Childhoodvasculitides,systemicarterialdysfunctionand,1372–1373
Children
acuteandchronicrenalconsequencesofcardiacdiseasein,1421–1427
estimatedenergyfor,1498t
proteinrequirementsfor,1498t
radiationdoseoptimizationin,333
Chi-squaretest,414
Chlorothiazideforhypertension,1140t
Choking,vascularringsand,888
Cholesterolesterstoragedisease,cardiacinvolvementin,1093
Chorangiosis,placental-to-birthweightratiosin,160,160f
Chromosomalabnormalities,prevalenceofcongenitalheartdisease,177
Chromosomalanomalies,1407–1410,1408t
deletion8P23syndrome,1410,1410f–1411f,1410t
Downsyndrome,1407–1409
Trisomy13andTrisomy18,1409–1410
Turnersyndrome,1409,1409f,1409t
Chromosome22q11deletionsyndrome,886
Chronicheartfailure,1193–1203
basicconceptsof,1193,1194f
cardiacmyocyte,cellularphysiologyof,1197–1198
normalandthefailingheart,functionof,1193–1196,1194f
cardiacfunctionwiththepressure-volumeloop,examinationof,1195–1196,1196f
otherorgansandmediatorsin,1198
sodiumandwater,retentionof,1198
sympatheticnervoussystem,1198
pediatric,outcomeof,1203
treatmentof,1198–1203
angiotensinreceptor/neprilysininhibitorsfor,1201,1201f
β-blockersfor,1200–1201,1200f–1201f
cardiacresynchronizationtherapyfor,1201–1202
digoxinfor,1199
diureticsfor,1199
reducingsuddendeath,1202–1203,1202f,1203t
renin-angiotensinsystem,inhibitorsof,1199–1200
Chroniclungdisease,pulmonaryhypertensionassociatedwith,207,1385–1386
Chronicmechanicalcirculatorysupport,1205–1216
long-term,currentdevicesfor,1208–1210
BerlinHeartEXCORin,1208,1208f
continuousflowventricularassistdevicesin,1209
futuredevicesand,1210
HeartMateIIin,1209
HVADin,1209–1210
totalartificialheartin,1208–1209
patientselectionfor,1205–1206,1206f
supportstrategiesin,1205–1206
perioperativemanagementwith,1214–1216
outpatientmanagementand,1215–1216
short-term,currentdevicesfor,1206–1208,1207f
inspecialpopulations,1210–1214
adultcongenitalheartdisease,1214
BiVADversusLVADsupport,1210
congenitalheartdisease,1210–1211
elevatedpulmonaryvascularresistance,1213–1214
singleventriclehearts,1211–1213,1212f,1213t
Chronicrenalconsequences,ofcardiacdiseaseinchildren,1421–1427
cardiorenalsyndromes,classificationof,1421–1427,1422t
Chronicrheumaticheartdisease,1023–1041
backgroundandepidemiologyof,1023,1024f
cardiacmagneticresonanceimagingin,1031–1032
chronicprogression,1026
clinicalassessmentof,1026–1027
complicationsof,1032
diagnosticcriteriafor,1023–1026
insettingofdocumentedepisodeofARF,1024,1025b
withoutprevioushistoryofARF,1026
echocardiographicscreeningof,1038–1039
echocardiographyand,1027–1031
aorticvalvedisease,1027–1030,1030b,1031f
cardiosurgicalintervention,1031,1032f
mitralvalvedisease,1027,1028f–1030f,1028b
progression/resolutionmonitoring,1031
pulmonaryvalvedisease,1030
tricuspidvalvedisease,1030
valvularseveritygrading,1030–1031
establishingcentersfor,1039–1041,1041b
managementof
medical,1032–1034
percutaneousstrategiesfor,1034–1036
surgeryfor,1036–1037,1037t
pathogenesisof,1023,1025f
Chronotropicincompetence,inFontancirculation,1322
CHSS,CongenitalHeartSurgeons'Society
Chylopericardium,1070
